Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Xeris Biopharma Holdings (XERS) Cost of Revenue (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Cost of Revenue for 6 consecutive years, with $10.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cost of Revenue rose 15.5% year-over-year to $10.9 million, compared with a TTM value of $42.6 million through Dec 2025, up 15.58%, and an annual FY2025 reading of $42.6 million, up 15.58% over the prior year.
  • Cost of Revenue was $10.9 million for Q4 2025 at Xeris Biopharma Holdings, roughly flat from $11.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $13.6 million in Q3 2024 and bottomed at $1.8 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $7.2 million, with a median of $6.9 million recorded in 2022.
  • The sharpest move saw Cost of Revenue skyrocketed 243.54% in 2022, then decreased 19.11% in 2025.
  • Year by year, Cost of Revenue stood at $4.9 million in 2021, then grew by 28.68% to $6.3 million in 2022, then grew by 20.33% to $7.6 million in 2023, then rose by 25.2% to $9.5 million in 2024, then increased by 15.5% to $10.9 million in 2025.
  • Business Quant data shows Cost of Revenue for XERS at $10.9 million in Q4 2025, $11.0 million in Q3 2025, and $11.9 million in Q2 2025.